Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP)

Blood

Volumn 110, Issue 10, 2007, Pages 3526-3531

  Boruchov, Donna M ^a   Gururangan, Sri ^b   Driscoll, M Catherine ^c   Bussel, James B ^d,e  

^a BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; DANAZOL; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISONE; RHESUS D ANTIBODY; STEROID; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFLAMMATION; LEUKEMIA; LEUKOPENIA; LONG TERM CARE; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE COUNT; TRANSAMINITIS; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 36348946412     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-01-065763     Document Type: Article

References (29)

1. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood. 2005;106:2244-2251.
2. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102:887-895.
3. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103:1364-1369.
4. Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol. 2006;133:364-374.
5. Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000;160:1630-1638.
6. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97:2549-2554.
7. George JN, Kojouri K, Perdue JJ, Vesely SK. Management of patients with chronic, refractory idiopathic thrombocytopenic purpura. Semin Hematol. 2000;37:290-298.
8. Schreiber AD, Chien P, Tomaski A, Cines DB. Effect of danazol in immune thrombocytopenic purpura. N Engl J Med. 1987;316:503-508.
9. Maloisel F, Andres E, Zimmer J, et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med. 2004;116:590-594.
10. Weinblatt ME, Kochen J, Ortega J. Danazol for children with immune thrombocytopenic purpura. Am J Dis Child. 1988;142:1317-1319.
11. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104:2623-2634.
12. Ahn YS, Horstman LL, Jy W, Jimenez JJ, Bowen B. Vascular dementia in patients with immune thrombocytopenic purpura. Thromb Res. 2002;107:337-344.
13. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis- stimulating protein, for chronic ITP. N Engl J Med. 2006;355:1672-1681.
14. Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol. 2006;81:19-25.
15. Zhang WG, Ji L, Cao XM, et al. Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura. Acta Pharmacol Sin. 2005;26:598-602.
16. Hou M, Peng J, Shi Y, et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol. 2003;70:353-357.
17. Levy AS, Cunningham-Rundles S, Mazza B, Simm M, Gorlick R, Bussel J. High P-glycoprotein-mediated export observed in patients with a history of idiopathic thrombocytopenic purpura. Br J Haematol. 2002;118:836-838.
18. Cooper N, Heddle NM, Haas M, et al. Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms. Br J Haematol. 2004;124:511-518.
19. Crow AR, Song S, Siragam V, Lazarus AH. Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia. Pediatr Blood Cancer. 2006;47:710-713.
20. Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apher Sci. 2003;28:249-255.
21. Berchtold P, Muller D, Beardsley D, et al. International study to compare antigen-specific methods used for the measurement of antiplatelet autoantibodies. Br J Haematol. 1997;96:477-483.
22. Medeiros D, Buchanan GR. Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome. J Pediatr. 1998;133:334-339.
23. Cosgriff TM, Black ML, Stein W III. Successful treatment of severe refractory idiopathic thrombocytopenic purpura with liposomal doxorubicin. Am J Hematol. 1998;57:85-86.
24. Figueroa M, Gehlsen J, Hammond D, et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med. 1993;328:1226-1229.
25. Kappers-Klunne MC, van't Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol. 2001;114:121-125.
26. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125:232-239.
27. Patel V, Mihatov N, Cooper N, Stasi R, Cunningham-Rundles S, Bussel JB. Long term follow-up of patients with immune thrombocytopenic purpura (ITP) whose initial response to rituximab lasted a minimum of 1 year. Blood (ASH Annual Meeting Abstracts). 2006;108:479.
28. Cooper N,Woloski BM, Fodero EM, et al. Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy? Blood. 2002;99:1922-1927.
29. George JN, Raskob GE, Vesely SK, et al. Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol. 2003;74:161-169.